Cargando…

Impact of Clinical Parameters and Induction Regimens on Peripheral Blood Stem-Cell Mobilization and Collection in Multiple Myeloma Patients

INTRODUCTION: High-dose chemotherapy (HDCT) followed by autologous blood stem-cell transplantation (ABSCT) remains the standard consolidation therapy for newly diagnosed eligible multiple myeloma (MM) patients. As a prerequisite, peripheral blood stem cells (PBSCs) must be mobilized and collected by...

Descripción completa

Detalles Bibliográficos
Autores principales:	Sauer, Sandra, Hieke, Lennart, Brandt, Juliane, Müller-Tidow, Carsten, Schmitt, Anita, Kauer, Joseph, Kriegsmann, Katharina
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	S. Karger AG 2023
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10601599/ https://www.ncbi.nlm.nih.gov/pubmed/37899996 http://dx.doi.org/10.1159/000530056

Ejemplares similares

Autologous Stem Cell Collection after Daratumumab, Bortezomib, Thalidomide, and Dexamethasone versus Bortezomib, Cyclophosphamide, and Dexamethasone in Newly Diagnosed Multiple Myeloma
por: Sauer, Sandra, et al.
Publicado: (2023)

Stem cell collection after lenalidomide, bortezomib and dexamethasone plus elotuzumab or isatuximab in newly diagnosed multiple myeloma patients: a single centre experience from the GMMG-HD6 and -HD7 trials
por: Kauer, Joseph, et al.
Publicado: (2023)

Quality of Online Information on Multiple Myeloma Available for Laypersons
por: Staemmler, Henrike, et al.
Publicado: (2022)

Low-dose peripheral blood stem cell graft after high-dose chemotherapy - an evaluation of hematopoietic reconstitution
por: Sauer, Sandra, et al.
Publicado: (2020)

Cell-based immunotherapy approaches for multiple myeloma
por: Kriegsmann, Katharina, et al.
Publicado: (2018)

Stem Cell Mobilization, Collection, and Processing
por: Kriegsmann, Katharina, et al.
Publicado: (2023)

A comparison of peripheral blood stem cell collection outcomes for multiple myeloma; mobilization matters in the era of IMiD induction
por: Chandler, Thea, et al.
Publicado: (2023)

Optimal chemo-mobilization for the collection of peripheral blood stem cells in patients with multiple myeloma
por: Song, Ga-Young, et al.
Publicado: (2019)

Antibiotic Prophylaxis or Granulocyte-Colony Stimulating Factor Support in Multiple Myeloma Patients Undergoing Autologous Stem Cell Transplantation
por: Klein, Eva-Maria, et al.
Publicado: (2021)

Impact of novel agent therapies on immune cell subsets and infectious complications in patients with relapsed/refractory multiple myeloma
por: John, Lukas, et al.
Publicado: (2023)

The impact of multiple myeloma induction therapy on hematopoietic stem cell mobilization and collection: 25-year experience
por: Figueiredo, Amarilis, et al.
Publicado: (2019)

Outcomes of autologous transplantation for multiple myeloma according to different induction regimens
por: de Queiroz Crusoe, Edvan, et al.
Publicado: (2014)

Comparison of NGS and MFC Methods: Key Metrics in Multiple Myeloma MRD Assessment
por: Kriegsmann, Katharina, et al.
Publicado: (2020)

Impact of daratumumab-based induction on stem cell collection parameters in Swedish myeloma patients
por: Lemonakis, Konstantinos, et al.
Publicado: (2022)

Comment on “Outcomes of autologous transplantation for multiple myeloma according to different induction regimens”
por: de la Rubia, Javier
Publicado: (2014)

A Comparison of Different Sample Processing Protocols for MALDI Imaging Mass Spectrometry Analysis of Formalin-Fixed Multiple Myeloma Cells
por: Casadonte, Rita, et al.
Publicado: (2023)

Selective elimination of immunosuppressive T cells in patients with multiple myeloma
por: Awwad, Mohamed H. S., et al.
Publicado: (2021)

Novel panel of protein biomarkers to predict response to bortezomib-containing induction regimens in multiple myeloma patients
por: Ting, Kay Reen, et al.
Publicado: (2017)

Induction Therapy and Stem Cell Mobilization in Patients with Newly Diagnosed Multiple Myeloma
por: Ria, Roberto, et al.
Publicado: (2012)

Induction therapy and stem-cell mobilization in myeloma, look at the past to plan the future()
por: Schaffel, Rony
Publicado: (2019)

Circadian disruption and divergent microbiota acquisition under extended photoperiod regimens in chicken
por: Hieke, Anne-Sophie Charlotte, et al.
Publicado: (2019)

Emerging agents and regimens for multiple myeloma
por: Yang, Yang, et al.
Publicado: (2020)

Mobilization and Hematopoietic Stem Cell Collection in Poor Mobilizing Patients with Lymphoma: Final Results of the German OPTIMOB Study
por: Kriegsmann, Katharina, et al.
Publicado: (2023)

Effectiveness of a vitamin D regimen in deficient multiple myeloma patients and its effect on peripheral neuropathy
por: Oortgiesen, Berdien E., et al.
Publicado: (2023)

Current Challenges in Providing Good Leukapheresis Products for Manufacturing of CAR-T Cells for Patients with Relapsed/Refractory NHL or ALL
por: Korell, Felix, et al.
Publicado: (2020)

Accuracy and Reliability of Internet Resources for Information on Monoclonal Gammopathy of Undetermined Significance—What Information Is out There for Our Patients?
por: Kreutzer, Emma Pauline, et al.
Publicado: (2021)

Peripheral blood stem cell mobilization in multiple myeloma: Growth factors or chemotherapy?
por: Wallis, Whitney D, et al.
Publicado: (2017)

Cereblon-binding proteins expression levels correlate with hyperdiploidy in newly diagnosed multiple myeloma patients
por: Kriegsmann, Katharina, et al.
Publicado: (2019)

Aspirin use and bleeding events during thrombocytopenia after autologous stem-cell transplantation for multiple myeloma
por: Neuendorff, Nina Rosa, et al.
Publicado: (2023)

Prolonged Lenalidomide Induction Does Not Significantly Impair Stem Cell Collection in Multiple Myeloma Patients Mobilized With Cyclophosphamide or Plerixafor: A Report From The Covid Era
por: Rybinski, Brad, et al.
Publicado: (2022)

Infection Complications after Lymphodepletion and Dosing of Chimeric Antigen Receptor T (CAR-T) Cell Therapy in Patients with Relapsed/Refractory Acute Lymphoblastic Leukemia or B Cell Non-Hodgkin Lymphoma
por: Korell, Felix, et al.
Publicado: (2021)

VAD Chemotherapy versus Bortezomib Containing Regimens as Remission Induction For ASCT in Multiple Myeloma: A Single Center Experience
por: Yıkılmaz, Aysun Şentürk, et al.
Publicado: (2020)

Carfilzomib, Lenalidomide, and Dexamethasone Followed by Salvage Autologous Stem Cell Transplant with or without Maintenance for Relapsed or Refractory Multiple Myeloma
por: Baertsch, Marc-Andrea, et al.
Publicado: (2021)

Autologous peripheral blood stem cell mobilization and collection in patients with lymphoma and multiple myeloma: A single-center experience using the plerixa for pre-emptive approach
por: Alsaeed, Ahmad S., et al.
Publicado: (2022)

Efficiency and Tolerability of Induction and Consolidation Therapy with Arsenic Trioxide/Bortezomib/Ascorbic Acid/Dexamethasone (ABCD) Regimen Compared to Bortezomib/Dexamethasone (BD) Regimen in Newly Diagnosed Myeloma Patients
por: Qian, Wensi, et al.
Publicado: (2020)

Induction regimens for transplant-eligible patients with newly diagnosed multiple myeloma: a network meta-analysis of randomized controlled trials
por: Zeng, Zi-Hang, et al.
Publicado: (2017)

Overall survival of transplant eligible patients with newly diagnosed multiple myeloma: comparative effectiveness analysis of modern induction regimens on outcome
por: Paquin, Ashley R., et al.
Publicado: (2018)

Comparison of bone marrow and peripheral blood aberrant plasma cell assessment by NGF in patients with MM
por: Kriegsmann, Katharina, et al.
Publicado: (2022)

Outcomes of poor peripheral blood stem cell mobilizers with multiple myeloma at the first mobilization: A multicenter retrospective study in Japan
por: Miyamoto‐Nagai, Yurie, et al.
Publicado: (2022)

Impact of serum-free media on the expansion and functionality of CD19.CAR T-cells
por: Eberhardt, Franziska, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_fnjl8pukn3v9u5tr5mbrjig8dr